AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Recommendation of “Buy” by Brokerages

Shares of AtriCure, Inc. (NASDAQ:ATRCGet Rating) have received an average rating of “Buy” from the thirteen research firms that are currently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $92.22.

A number of analysts recently issued reports on ATRC shares. Needham & Company LLC restated a “buy” rating and set a $79.00 price objective on shares of AtriCure in a report on Thursday, February 24th. BTIG Research reissued a “buy” rating and set a $94.00 price objective on shares of AtriCure in a report on Monday, March 14th. TheStreet lowered AtriCure from a “b-” rating to a “c” rating in a report on Wednesday, February 16th. Canaccord Genuity Group reduced their price objective on AtriCure from $120.00 to $88.00 in a report on Wednesday, February 16th. Finally, Canaccord Genuity Group cut their target price on shares of AtriCure from $120.00 to $88.00 and set a “buy” rating for the company in a research report on Wednesday, February 16th.

NASDAQ:ATRC opened at $57.05 on Friday. The firm has a 50-day moving average of $64.14 and a 200-day moving average of $68.30. AtriCure has a one year low of $55.85 and a one year high of $89.18. The company has a market cap of $2.64 billion, a PE ratio of 53.32 and a beta of 1.10. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.47 and a quick ratio of 2.78.

AtriCure (NASDAQ:ATRCGet Rating) last announced its quarterly earnings results on Tuesday, February 15th. The medical device company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.04). AtriCure had a negative return on equity of 11.96% and a net margin of 18.30%. The company had revenue of $73.22 million for the quarter, compared to the consensus estimate of $72.50 million. During the same quarter last year, the company posted ($0.18) EPS. On average, equities research analysts expect that AtriCure will post -1.09 earnings per share for the current fiscal year.

In other AtriCure news, insider Tonya Austin sold 2,490 shares of the business’s stock in a transaction dated Friday, February 11th. The stock was sold at an average price of $67.97, for a total transaction of $169,245.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 5,807 shares of company stock valued at $394,645 over the last 90 days. Corporate insiders own 5.80% of the company’s stock.

A number of hedge funds have recently bought and sold shares of ATRC. Morgan Stanley lifted its stake in shares of AtriCure by 121.5% in the 2nd quarter. Morgan Stanley now owns 138,946 shares of the medical device company’s stock valued at $11,022,000 after purchasing an additional 76,206 shares during the last quarter. State of New Jersey Common Pension Fund D raised its position in shares of AtriCure by 6.0% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 36,260 shares of the medical device company’s stock worth $2,522,000 after acquiring an additional 2,065 shares in the last quarter. SG Americas Securities LLC raised its position in shares of AtriCure by 20.6% in the 3rd quarter. SG Americas Securities LLC now owns 10,157 shares of the medical device company’s stock worth $706,000 after acquiring an additional 1,738 shares in the last quarter. Raymond James & Associates raised its stake in shares of AtriCure by 6.0% during the 3rd quarter. Raymond James & Associates now owns 24,771 shares of the medical device company’s stock worth $1,723,000 after acquiring an additional 1,401 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in shares of AtriCure by 12.2% during the 3rd quarter. Deutsche Bank AG now owns 67,705 shares of the medical device company’s stock worth $4,709,000 after acquiring an additional 7,364 shares in the last quarter. Institutional investors and hedge funds own 93.28% of the company’s stock.

About AtriCure (Get Rating)

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.

Read More

Analyst Recommendations for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.